NASDAQ:ZIOP

ZIOPHARM Oncology Stock Forecast, Price & News

$3.13
-0.01 (-0.32 %)
(As of 04/20/2021 01:13 PM ET)
Add
Compare
Today's Range
$3.07
Now: $3.13
$3.23
50-Day Range
$3.26
MA: $3.92
$5.33
52-Week Range
$2.06
Now: $3.13
$5.95
Volume50,576 shs
Average Volume2.71 million shs
Market Capitalization$673.59 million
P/E RatioN/A
Dividend YieldN/A
Beta2.28
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
ZIOPHARM Oncology logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ZIOP
CUSIP98973P10
Phone617-259-1970
Employees103
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Book Value$0.52 per share

Profitability

Net Income$-117,800,000.00

Miscellaneous

Market Cap$673.59 million
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

Headlines

ZIOP Apr 2021 4.500 call
April 4, 2021 |  uk.finance.yahoo.com
Why Ziopharm Oncology Stock Is Sinking Today
March 20, 2021 |  finance.yahoo.com
Ziopharm Oncology IncShs Hold
March 14, 2021 |  markets.businessinsider.com
Why Ziopharm Oncology Stock Is Jumping Today
February 26, 2021 |  finance.yahoo.com
Analyzing ZIOPHARM Oncology's Unusual Options Activity
February 8, 2021 |  finance.yahoo.com
Ziopharm to Participate in Upcoming January Conferences
December 23, 2020 |  finance.yahoo.com
Ziopharm Comments on Consent Solicitation Results
December 16, 2020 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.29 out of 5 stars

Medical Sector

825th out of 2,018 stocks

Pharmaceutical Preparations Industry

394th out of 772 stocks

Analyst Opinion: 3.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$3.13
-0.01 (-0.32 %)
(As of 04/20/2021 01:13 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZIOP News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions

Is ZIOPHARM Oncology a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ZIOPHARM Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZIOP, but not buy additional shares or sell existing shares.
View analyst ratings for ZIOPHARM Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than ZIOPHARM Oncology?

Wall Street analysts have given ZIOPHARM Oncology a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ZIOPHARM Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is ZIOPHARM Oncology's next earnings date?

ZIOPHARM Oncology is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for ZIOPHARM Oncology
.

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) posted its quarterly earnings results on Thursday, February, 25th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.01.
View ZIOPHARM Oncology's earnings history
.

How has ZIOPHARM Oncology's stock price been impacted by Coronavirus?

ZIOPHARM Oncology's stock was trading at $2.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ZIOP stock has increased by 23.2% and is now trading at $3.13.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ZIOP?

5 brokers have issued 1-year price targets for ZIOPHARM Oncology's stock. Their forecasts range from $5.00 to $7.50. On average, they anticipate ZIOPHARM Oncology's share price to reach $5.90 in the next year. This suggests a possible upside of 88.5% from the stock's current price.
View analysts' price targets for ZIOPHARM Oncology
or view top-rated stocks among Wall Street analysts.

Who are ZIOPHARM Oncology's key executives?

ZIOPHARM Oncology's management team includes the following people:
  • Ms. Heidi M. Hagen, Interim CEO, Principal Exec. Officer & Director (Age 52, Pay $32.4k)
  • Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 65, Pay $402.57k)
  • Mr. Robert Hadfield, Chief Legal Officer & Sec. (Age 43, Pay $517.72k)
  • Dr. David M. Mauney M.D., Consultant (Age 52, Pay $686.01k)
  • Mr. James Huang M.B.A., Exec. Chairman (Age 55)
  • Mr. Timothy M. Cunningham, Interim CFO & Principal Financial Officer (Age 59)
  • Ms. Lynn M. Ferrucci, Exec. VP of HR, Facilities, Admin. & IT
  • Christopher Taylor, VP of Investor Relations & Corp. Communications
  • Dr. Adam D. Levy M.B.A., Ph.D., Exec. VP of Investor Relations & Corp. Communications
  • Ms. Jill Buck, Exec. VP & GM of Gene Therapy (Age 47)

Who are some of ZIOPHARM Oncology's key competitors?

What other stocks do shareholders of ZIOPHARM Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (gild), OPKO Health (OPK), (CELG), Sangamo Therapeutics (SGMO), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU).

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

How do I buy shares of ZIOPHARM Oncology?

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ZIOPHARM Oncology's stock price today?

One share of ZIOP stock can currently be purchased for approximately $3.13.

How much money does ZIOPHARM Oncology make?

ZIOPHARM Oncology has a market capitalization of $673.59 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-117,800,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does ZIOPHARM Oncology have?

ZIOPHARM Oncology employs 103 workers across the globe.

What is ZIOPHARM Oncology's official website?

The official website for ZIOPHARM Oncology is www.ziopharm.com.

Where are ZIOPHARM Oncology's headquarters?

ZIOPHARM Oncology is headquartered at ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129.

How can I contact ZIOPHARM Oncology?

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]


This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.